Tevogen Bio Holdings Inc. (TVGN) Financial Ratios
4 years of historical data (2021–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 14067.48
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
N/A
—
5yr avg: N/A
Debt/EBITDA
N/A
—
5yr avg: 9.08
30Y Low9.1·High9.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TVGN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Tevogen Bio Holdings Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $1.5B | $7.6B | $92.1B | $62.0B | — |
| Enterprise Value | $1.5B | $7.6B | $92.2B | $62.0B | — |
| P/E Ratio → | -79.91 | — | — | 14073.57 | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TVGN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | 14067.48 | — |
| EV / EBIT | — | — | — | 14067.48 | — |
| EV / FCF | — | — | — | — | — |
TVGN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | — | — | — | — | — |
| ROA | -225.6% | -225.6% | -913.2% | 57.3% | -203.7% |
| ROIC | — | — | -2597.2% | -322.2% | — |
| ROCE | — | — | — | -14.9% | -66.1% |
TVGN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $2M ($3M total debt minus $1M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — |
| Debt / EBITDA | — | — | — | 9.08 | — |
| Net Debt / Equity | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | 7.83 | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -291.05 | -291.05 | -34.54 | — | -7.72 |
TVGN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.26x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.98x to 0.26x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 0.26 | 0.26 | 0.02 | 2.98 | 10.74 |
| Quick Ratio | 0.26 | 0.26 | 0.02 | 2.98 | 10.74 |
| Cash Ratio | 0.14 | 0.14 | 0.01 | 2.80 | 10.66 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
TVGN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Tevogen Bio Holdings Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 0.0% | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.4% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.4% | 0.0% | — |
| Shares Outstanding | — | $147M | $165M | $120M | $48M |
Peer Comparison
Compare TVGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TVGNYou | $1B | -79.9 | — | — | — | — | — | — | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 ADMA | $2B | 14.1 | 10.1 | 73.1 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 DYAI | $27M | -3.7 | — | — | 65.8% | -168.8% | -139.2% | -1669.3% | — |
 VXRT | $178M | 10.6 | 7.4 | 23.5 | — | 7.6% | 22.3% | 27.1% | 0.5 |
 OCGN | $487M | -6.3 | — | — | 45.9% | -1425.7% | -776.9% | -1565.6% | — |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See TVGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TVGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TVGN vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonTVGN — Frequently Asked Questions
Quick answers to the most common questions about buying TVGN stock.
What is Tevogen Bio Holdings Inc.'s P/E ratio?
Tevogen Bio Holdings Inc.'s current P/E ratio is -79.9x. This places it at the 50th percentile of its historical range.
Is TVGN stock overvalued?
Based on historical data, Tevogen Bio Holdings Inc. is trading at a P/E of -79.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.